Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.PLX · Entity 2671 | Sr. VP & COO | September 03, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protalix BioTherapeutics, Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.59 · Expires 2036-09-03 | Direct | 112,000 |
Reported balance
After 2026-09-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-03 · Grant · Acquired 112,000 · Balance 112,000 F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. F2: Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034, and (v) options to purchase 50,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 56,000 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Grant · Acquired 56,000 · Balance 56,000 F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
F2: Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034, and (v) options to purchase 50,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 4, 2026 10:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantRestricted Stock Units · Derivative | 56,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001742727-26-000002 · form4-09042026_060917.xml · derivative · entry 2 Naos Yaron · CIK 0001742727 · Sr. VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 10:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001742727-26-000002 · form4-09042026_060917.xml · derivative · entry 1 Naos Yaron · CIK 0001742727 · Sr. VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2036-09-03 F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. F2 · balance_after: Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034, and (v) options to purchase 50,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-25-023701 · form4-09042025_050903.xml · derivative · entry 3 Naos Yaron · CIK 0001742727 · Sr. VP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-09-03 F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F4 · balance_after: Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023701 · form4-09042025_050903.xml · nonDerivative · entry 1 Naos Yaron · CIK 0001742727 · Sr. VP, Operations 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 225,817 F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001415889-24-023906 · form4-09242024_050902.xml · derivative · entry 1 Naos Yaron · CIK 0001742727 · Sr. VP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-09-23 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 and (iv) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:30 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 187,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-093066 · tm2324046-1_4seq1.xml · nonDerivative · entry 1 Naos Yaron · CIK 0001742727 · Sr. VP, Operations 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 200,817 F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 21:04 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-22-098953 · tm2225460-9_4seq1.xml · derivative · entry 1 Naos Yaron · CIK 0001742727 · Sr. VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2032-09-07 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028 and (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 21:01 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 122,656 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001104659-20-094751 · tm2027548d1_4.xml · derivative · entry 1 Naos Yaron · CIK 0001742727 · Sr. VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,656 Underlying: Common Stock · 122,656 shares Expires 2030-08-11 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025 and (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 20:30 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001144204-18-049521 · tv502882_4.xml · derivative · entry 1 Naos Yaron · CIK 0001742727 · Sr. VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2028-09-13 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 115,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.